Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio Pharmaceuticals said the FDA continues to review its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis. The FDA's target action date is Oct. 30, making the pending regulatory decision a potential near-term catalyst for INO shares.